Status:
COMPLETED
A Trial of the ALK Grass Tablet in Subjects With Hayfever
Lead Sponsor:
ALK-Abelló A/S
Conditions:
Allergy
Eligibility:
All Genders
18-65 years
Phase:
PHASE3
Brief Summary
This trial is performed to assess the efficacy and safety of the ALK Grass tablet for treatment of grass pollen induced rhinoconjunctivitis (hayfever).
Eligibility Criteria
Inclusion
- Eligibility Criteria:
- A history of grass pollen induced rhinoconjunctivitis
- Positive skin prick test to grass
- Positive specific IgE to grass
Exclusion
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
634 Patients enrolled
Trial Details
Trial ID
NCT00227279
Start Date
October 1 2004
End Date
September 1 2009
Last Update
January 29 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Lungemedicinsk Forskningsafdeling, Aarhus Kommunehospital
Aarhus C, Denmark, 8000